Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson’s disease

Daisuke Doi, Hiroaki Magotani, Tetsuhiro Kikuchi, Megumi Ikeda, Satoe Hiramatsu, Kenji Yoshida, Naoki Amano, Masaki Nomura, Masafumi Umekage, Asuka Morizane and Jun Takahashi ()
Additional contact information
Daisuke Doi: Kyoto University
Hiroaki Magotani: Kyoto University
Tetsuhiro Kikuchi: Kyoto University
Megumi Ikeda: Kyoto University
Satoe Hiramatsu: Kyoto University
Kenji Yoshida: Kyoto University
Naoki Amano: Kyoto University
Masaki Nomura: Kyoto University
Masafumi Umekage: Kyoto University
Asuka Morizane: Kyoto University
Jun Takahashi: Kyoto University

Nature Communications, 2020, vol. 11, issue 1, 1-14

Abstract: Abstract Induced pluripotent stem cell (iPSC)-derived dopaminergic (DA) neurons are an expected source for cell-based therapies for Parkinson’s disease (PD). The regulatory criteria for the clinical application of these therapies, however, have not been established. Here we show the results of our pre-clinical study, in which we evaluate the safety and efficacy of dopaminergic progenitors (DAPs) derived from a clinical-grade human iPSC line. We confirm the characteristics of DAPs by in vitro analyses. We also verify that the DAP population include no residual undifferentiated iPSCs or early neural stem cells and have no genetic aberration in cancer-related genes. Furthermore, in vivo studies using immunodeficient mice reveal no tumorigenicity or toxicity of the cells. When the DAPs are transplanted into the striatum of 6-OHDA-lesioned rats, the animals show behavioral improvement. Based on these results, we started a clinical trial to treat PD patients in 2018.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-17165-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17165-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-17165-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().